BRUSSELS, BELGIUM / RankWire.AI / – The European Commission has broadened its initiative to combat Ebola by acquiring €2.1 million worth of PCR tests specifically for the Bundibugyo virus outbreak. This procurement involves open-platform testing kits designed to be compatible with existing laboratory systems. The procurement process received backing from the European Health and Digital Executive Agency. Dispatches are scheduled to commence in August, as health authorities face a significant outbreak centered in the Democratic Republic of the Congo, affecting surrounding regions.
The World Health Organization will facilitate the distribution of these tests through its Hub for Global Health Emergencies Logistics located in Dubai. Subsequently, WHO will oversee the allocation of tests to various sites involved in the Ebola response. PCR diagnostics enable labs to verify infections precisely and bolster surveillance efforts around confirmed cases. Confirmed test results are vital for guiding patient management, implementing isolation protocols, and conducting contact tracing. This latest batch of supplies bolsters laboratory capacity during a time when authorities are actively monitoring ongoing transmission across multiple provinces and health zones in the Democratic Republic of the Congo.
Previously, the European Commission arranged an additional package valued at €2.5 million, consisting of rapid molecular point-of-care testing devices and related equipment. This apparatus is intended to support the Africa Centres for Disease Control and Prevention in their regional Ebola containment efforts. The combined value of these two diagnostic agreements now totals €4.6 million. They form part of a broader European support package aimed at assisting countries affected by the Bundibugyo Ebola emergency. This aid encompasses medical supplies, preparedness initiatives, and public health resources, all designed to strengthen the overall response in affected and neighboring areas.
Laboratory Testing Capacity Expands Amid Major Outbreak
As of August 12, WHO reports indicate that the Democratic Republic of the Congo has confirmed 4,665 cases of Ebola and recorded 2,184 fatalities. Infections have been identified across 54 health zones within six provinces, including Ituri, North Kivu, South Kivu, Haut-Uélé, Tshopo, and Bas-Uélé. WHO described this as the largest Ebola epidemic ever documented in the country. The organization also noted ongoing transmission across interconnected geographic clusters, which continues to place significant demands on surveillance teams, laboratories, treatment centers, and local health infrastructure.
In its August update, WHO maintained a very high national risk assessment for the Democratic Republic of the Congo, categorizing the threat to neighboring countries as high while deeming the risk elsewhere as low. Following a meeting of its International Health Regulations Emergency Committee on August 24, WHO issued updated temporary guidance covering surveillance, case detection, infection prevention, clinical management, and community engagement. The recommendations also address mobility restrictions and the management of large gatherings during this ongoing crisis.
European Support for Ebola Response Tops €493 Million
The European Commission announced that it has allocated €493 million to emergency aid efforts, including vaccines, treatments, and health security measures across the Great Lakes region and Uganda. European health agencies also contribute to laboratory diagnostics, surveillance activities, and preparedness programs. The European Centre for Disease Prevention and Control continues to assess the risk to populations in Europe as very low. Since Ebola primarily spreads through direct contact with infected bodily fluids, rapid detection, safe clinical procedures, and robust infection control are critical in limiting its transmission.
The ongoing Bundibugyo virus outbreak remains classified as a public health emergency of international concern under WHO’s international health framework. Currently, there is no approved vaccine or specific treatment targeting Bundibugyo virus disease. Consequently, health authorities rely heavily on surveillance, rapid diagnosis, patient isolation, clinical management, infection prevention, and vigilant contact monitoring. The newly supplied PCR testing capacity enhances this response. WHO, Africa CDC, and national health agencies continue to coordinate efforts to identify cases promptly and uphold public health measures in affected communities.